AMA
AMA (ISIN GB00BNKGC5 – ticker ALAMA), a pioneer in Assisted Reality solutions, and moziware, a provider of leading-edge wearable technologies of Industrial Metaverse today announced their global strategic partnership to reshape remote collaboration by combining AMA’s brand new XpertEye On & Live remote assistance solution with moziware’s next-gen cimo smart glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220905005323/en/
Strategic Partnership moziware - AMA
With AMA‘s XpertEye On & Live solution, it only takes just one click on cimo to start collaborating and benefit from full HD video quality with 1080p image resolution, extremely accurate white balance settings, and industrial noise cancellation. Equipped with AMA’s AR-powered remote collaboration solution and the cimo ultra-compact and lightweight smart glasses, frontline workers across manufacturing, audit, telco, healthcare, and other industries can remotely collaborate, complete complex tasks together, and resolve issues smarter, faster, and safer.
“moziware is honored to have AMA as our strategic partner. Through relentless teamwork, we have the latest XpertEye solution seamlessly integrated on cimo with exciting new features like one-button start. We believe the joint solution will revolutionize how frontline workers collaborate and operate in the industrial 4.0 era”, said Dr. Li Bo, CEO of moziware.
“AMA is proud to have teamed up with moziware since 2021 to propose today the latest in voice-activated, hands-free, remote collaboration. Our aggressively priced and easy-to-use solution will help improve safety, efficiency, and productivity of frontline workers around the world", said Christian Guillemot, co-founder and CEO of AMA.
About AMA
With eight years of proven experience in remote assistance solutions, AMA is helping medical institutions and industrial organizations of all sizes accelerate their digital transformation. Our market leading XpertEye Assisted Reality platform has been deployed in more than 100 countries, addressing a wide range of applications like remote diagnostics, inspection, scheduling, and workflow management. These unequaled remote interactive collaboration solutions empower our customers to improve productivity, speed up resolution time, and maximize uptime.
With offices in Europe, in the USA and in the APAC region, AMA can work in every time zone and reach its customers wherever they are.
AMA is listed on Euronext Growth Paris (GB00BNKGZC51 - ALAMA).
More information on www.amaxperteye.com
About mōziware
mōziware is a pioneer in accelerating digital transformation through leading-edge wearable technologies and solutions for the industrial sector and beyond.
Its mission is to create an ecosystem of solutions that leverage Augmented Reality (AR), Artificial Intelligence (AI), and Internet of Things (IoT) technologies to empower executives and frontline workers to make smarter, safer, and faster decisions, resulting in increased productivity, improved safety, optimized workflows, and reduced costs.
For more information, visit: https://moziware.io, contact us at info@moziware.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 13:00:00 CET | Press release
Expands Registrar Corp’s reach to support over 75% of the global medical device market. Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 13:00:00 CET | Press release
In a pre-IPO round led by Growth Equity at Goldman Sachs Alternatives and with significant participation from CapitalG, Armis accelerates on the path to $1 billion in ARR and a public offering Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Fo
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
Compass Pathways to Participate in Stifel 2025 Healthcare Conference5.11.2025 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP36
Watchmaker Genomics Launches TAPS+, Expanding Multimodal Capabilities in Oncology Ahead of AMP 20255.11.2025 12:00:00 CET | Press release
- TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. - Preserves DNA integrity in challenging clinically relevant samples, including FFPE tissue and circulating tumor DNA (ctDNA). - Platform-agnostic chemistry enables seamless integration across sequencing systems. Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105264633/en/ Watchmaker Genomics launches TAPS+, a next-gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom